StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a research report released on Wednesday. The firm issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Trading Down 25.5 %
Shares of BLPH opened at $0.01 on Wednesday. Bellerophon Therapeutics has a 12-month low of $0.01 and a 12-month high of $0.02. The company has a market cap of $146,796.00, a PE ratio of -0.01 and a beta of 0.74. The stock has a 50-day moving average price of $0.04 and a 200-day moving average price of $0.04.
Bellerophon Therapeutics Announces Dividend
The firm also recently disclosed a dividend, which was paid on Wednesday, December 18th. Stockholders of record on Friday, December 20th were given a $0.019 dividend. The ex-dividend date of this dividend was Thursday, December 19th. This represents a dividend yield of 117.8%.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Featured Stories
- Five stocks we like better than Bellerophon Therapeutics
- Learn Technical Analysis Skills to Master the Stock Market
- Stock Buybacks Outperform Dividends: Here’s the Key Advantage
- What is the Nikkei 225 index?
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- What Are Dividend Achievers? An Introduction
- Why Now Is the Ultimate Time to Invest in Oil Stocks
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
